A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes
Keymeulen B., et al.
November 2020
Authors and Affiliates
Bart Keymeulen 1,2, André van Maurik 3, Dave Inman 3, João Oliveira 4, Rene McLaughlin 5, Rachel M Gittelman 6, Bart O Roep 7,8, Pieter Gillard 9, Robert Hilbrands 10,11, Frans Gorus 10,11, Chantal Mathieu 9, Ursule Van de Velde 10,11, Nicolas Wisniacki 3, Antonella Napolitano 12;
1 Academic Hospital and Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium. bart.keymeulen@vub.be.
2 Belgian Diabetes Registry, Brussels, Belgium. bart.keymeulen@vub.be.
3 GlaxoSmithKline Medicines Research Centre, Stevenage, UK.
4 GlaxoSmithKline, Global Clinical Operations, Cambridge, UK.
5 Department of Immunology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.
6 Adaptive Biotechnologies, Seattle, WA, USA.
7 Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.
8 Department of Diabetes Immunology, Diabetes & Metabolism Research Institute, Beckman Research Institute at the City of Hope, Duarte, CA, USA.
9 Department of Endocrinology, University Hospitals Leuven-KUL, Leuven, Belgium.
10 Academic Hospital and Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium.
11 Belgian Diabetes Registry, Brussels, Belgium.
12 GlaxoSmithKline Medicines Research Centre, Stevenage, UK. Antonella.2.napolitano@gsk.com.